The Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million, according to IQVIA sales data for the 12-month period that ended in December 2024.
Purpose: We investigated the intraocular pressure (IOP) variations after switching from 0.005% latanoprost to 0.01% bimatoprost in open-angle glaucoma patients who experienced IOP elevation during ...
On the plus side, the Mont Blanc trial of the drug showed that it was as effective in treating the eye disease as prostaglandin analogue latanoprost 0.005%, a standard therapy for glaucoma ...
ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight
ROCKLATAN/ROCLANDA (netarsudil and latanoprost ophthalmic solution) 0.02% and 0.005% is a prescription drug used to lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results